Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mitral Valve Prolapse I: Introduction01:27

Mitral Valve Prolapse I: Introduction

912
IntroductionThe mitral valve, one of the heart's four valves, regulates blood flow. These valves have flaps that open and close to direct blood properly through the heart and body. During each heartbeat, the flaps open for blood to pass through and seal shut to prevent backflow. Specifically, the mitral valve opens to allow blood flow from the heart's upper left chamber to the lower left chamber. It then closes securely as the lower left chamber contracts to pump blood to the body, preventing...
912
Mitral Valve Prolapse II: Assessment and Management01:22

Mitral Valve Prolapse II: Assessment and Management

1.1K
IntroductionA range of clinical features characterizes Mitral Valve Prolapse (MVP), but it is important to note that many individuals with MVP are asymptomatic and may remain so throughout their lives. For those who do exhibit symptoms, the following are the key clinical features:Palpitations: This is a common symptom where individuals feel an irregular or rapid heartbeat. Palpitations in MVP are often due to arrhythmias such as premature ventricular contractions or supraventricular...
1.1K
Mitral Valve Prolapse III: Nursing Management01:19

Mitral Valve Prolapse III: Nursing Management

526
The nursing management of Mitral Valve Prolapse, or MVP, centers around patient education, symptom monitoring, and lifestyle modifications.Patient Education on MVP Diagnosis and Heredity: Nurses should provide comprehensive education about MVP, a condition where the mitral valve does not close appropriately during heartbeats. This education often includes the condition's pathophysiology, symptoms, and potential complications, like arrhythmias or mitral regurgitation. Though not fully...
526
Mitral Stenosis III: Medical Management01:26

Mitral Stenosis III: Medical Management

441
Mitral stenosis, a condition marked by the narrowing of the mitral valve, necessitates an integrated approach for effective management. This approach includes preventative measures, medical therapy, and surgical interventions to reduce symptoms and prevent complications.PreventionPrevention of mitral stenosis primarily focuses on reducing the incidence of bacterial infections, particularly streptococcal infections, which can lead to rheumatic fever and subsequent valvular damage. Timely...
441
Mitral Stenosis I: Introduction01:22

Mitral Stenosis I: Introduction

1.3K
Mitral Valve Stenosis (MVS) is a heart condition where the mitral valve narrows, impeding blood circulation from the left atrium to the left ventricle. The etiology and pathophysiology of this condition are multifaceted, leading to a cascade of cardiovascular complications.Causes of Mitral Valve StenosisRheumatic Heart Disease: It is the main cause of mitral valve stenosis, particularly in developing nations. This condition arises from rheumatic fever, an inflammatory illness resulting from...
1.3K
Mitral Stenosis II: Clinical features and Diagnostic Tests01:23

Mitral Stenosis II: Clinical features and Diagnostic Tests

425
Mitral stenosis is a heart condition in which the mitral valve, which allows blood to flow from the left atrium to the left ventricle, becomes narrowed or stenotic. This narrowing hinders blood flow and leads to clinical symptoms requiring specific medical evaluations and management strategies. The following overview outlines the clinical symptoms, assessments, diagnostic findings, prevention methods, and treatments for mitral stenosis.Clinical ManifestationsDyspnea (shortness of breath): This...
425

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Computed Tomography-Derived Fractional Flow Reserve Versus Transit-Time Flow Measurement for Predicting Early Competitive Graft Flow After Coronary Artery Bypass Grafting.

Interdisciplinary cardiovascular and thoracic surgery·2026
Same author

Coronary artery bypass grafting based on computed tomography-derived fractional flow reserve versus angiography: Early results.

The Annals of thoracic surgery·2026
Same author

Myocardial perfusion improvement of saphenous vein Y-composite versus aortocoronary grafts during the first year after surgery.

JTCVS open·2026
Same author

Fifteen-year patency and 18-year clinical outcomes after surgical revascularization using saphenous vein composite grafts to total arterial grafts.

The Journal of thoracic and cardiovascular surgery·2026
Same author

Nationwide Trends in Coronary Artery Bypass Grafting in the Republic of Korea, 2005-2022: A Comparison with International Data.

Journal of chest surgery·2025
Same author

Concomitant Ablation of Atrial Fibrillation in Redo Heart Valve Surgery.

Journal of chest surgery·2025

Related Experiment Video

Updated: Mar 26, 2026

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
08:31

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

Published on: October 16, 2021

4.6K

Patient-Prosthesis Mismatch After Mitral Valve Replacement: A Propensity Score Analysis.

Ho Young Hwang1, Yong Han Kim1, Kyung-Hwan Kim1

  • 1Department of Thoracic and Cardiovascular Surgery, Seoul National University Hospital, Seoul, Korea.

The Annals of Thoracic Surgery
|January 23, 2016
PubMed
Summary

Patient-prosthesis mismatch (PPM) after mitral valve replacement significantly impacts long-term survival and reduces freedom from cardiac death. This study highlights PPM as a critical risk factor affecting patient outcomes post-mitral valve replacement.

More Related Videos

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
12:17

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots

Published on: May 21, 2017

12.0K
Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
14:14

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement

Published on: December 11, 2017

14.9K

Related Experiment Videos

Last Updated: Mar 26, 2026

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair
08:31

A Simplified Stepwise Approach to Echo Guidance during Percutaneous Mitral Valve Repair

Published on: October 16, 2021

4.6K
Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots
12:17

Full-root Aortic Valve Replacement by Stentless Aortic Xenografts in Patients with Small Aortic Roots

Published on: May 21, 2017

12.0K
Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement
14:14

Standardized Technique of Aortic Valve Re-implantation for Valve-sparing Aortic Root Replacement

Published on: December 11, 2017

14.9K

Area of Science:

  • Cardiovascular Surgery
  • Biomedical Engineering
  • Clinical Outcomes Research

Background:

  • Patient-prosthesis mismatch (PPM) is a potential concern after mitral valve replacement (MVR).
  • The clinical impact of PPM on long-term outcomes following MVR requires thorough investigation.

Purpose of the Study:

  • To evaluate the effect of PPM after mitral valve replacement on clinical outcomes.
  • To utilize propensity score models for robust analysis of PPM impact.

Main Methods:

  • 760 patients undergoing MVR with mechanical or bioprosthetic valves were analyzed.
  • Mitral PPM defined as effective orifice area index ≤ 1.2 cm²/m², derived from literature data.
  • Propensity score methods (inverse probability of treatment weighting and matching) were employed for analysis over a median follow-up of 127 months.

Main Results:

  • Mitral PPM was present in 19.3% of patients, who were older with more comorbidities.
  • 10- and 20-year overall survival and freedom from cardiac death were lower in the PPM group.
  • Mitral PPM was a significant risk factor for overall survival (HR 1.681) and freedom from cardiac death (HR 1.673) in adjusted analyses.

Conclusions:

  • Mitral PPM significantly impairs long-term survival after mitral valve replacement.
  • Mitral PPM is independently associated with reduced freedom from cardiac death.
  • Mitral valve replacement outcomes are demonstrably affected by the presence of patient-prosthesis mismatch.